ID   ERN1_HUMAN              Reviewed;         977 AA.
AC   O75460; A1L457; A8K8N8; A8MXS7; Q59EE2;
DT   16-AUG-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-2008, sequence version 2.
DT   12-OCT-2022, entry version 210.
DE   RecName: Full=Serine/threonine-protein kinase/endoribonuclease IRE1 {ECO:0000305};
DE   AltName: Full=Endoplasmic reticulum-to-nucleus signaling 1 {ECO:0000303|PubMed:9637683};
DE   AltName: Full=Inositol-requiring protein 1 {ECO:0000303|PubMed:9637683};
DE            Short=hIRE1p {ECO:0000303|PubMed:9637683};
DE   AltName: Full=Ire1-alpha {ECO:0000303|PubMed:11779464};
DE            Short=IRE1a {ECO:0000303|PubMed:11779464};
DE   Includes:
DE     RecName: Full=Serine/threonine-protein kinase;
DE              EC=2.7.11.1 {ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:9637683};
DE   Includes:
DE     RecName: Full=Endoribonuclease;
DE              EC=3.1.26.- {ECO:0000269|PubMed:21317875};
DE   Flags: Precursor;
GN   Name=ERN1 {ECO:0000312|HGNC:HGNC:3449};
GN   Synonyms=IRE1 {ECO:0000312|EMBL:AAC25991.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAC25991.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, ACTIVITY REGULATION,
RP   COFACTOR, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AUTOPHOSPHORYLATION,
RP   GLYCOSYLATION, AND MUTAGENESIS OF LYS-599.
RC   TISSUE=Liver {ECO:0000312|EMBL:AAC25991.1};
RX   PubMed=9637683; DOI=10.1101/gad.12.12.1812;
RA   Tirasophon W., Welihinda A.A., Kaufman R.J.;
RT   "A stress response pathway from the endoplasmic reticulum to the nucleus
RT   requires a novel bifunctional protein kinase/endoribonuclease (Ire1p) in
RT   mammalian cells.";
RL   Genes Dev. 12:1812-1824(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Endothelial cell;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 2-977 (ISOFORM 2).
RC   TISSUE=Brain, and Leukocyte;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION.
RX   PubMed=11779464; DOI=10.1016/s0092-8674(01)00611-0;
RA   Yoshida H., Matsui T., Yamamoto A., Okada T., Mori K.;
RT   "XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress
RT   to produce a highly active transcription factor.";
RL   Cell 107:881-891(2001).
RN   [8]
RP   INTERACTION WITH TAOK3 AND TRAF2.
RX   PubMed=11278723; DOI=10.1074/jbc.m010677200;
RA   Yoneda T., Imaizumi K., Oono K., Yui D., Gomi F., Katayama T., Tohyama M.;
RT   "Activation of caspase-12, an endoplastic reticulum (ER) resident caspase,
RT   through tumor necrosis factor receptor-associated factor 2-dependent
RT   mechanism in response to the ER stress.";
RL   J. Biol. Chem. 276:13935-13940(2001).
RN   [9] {ECO:0000305}
RP   FUNCTION, AND MUTAGENESIS OF LYS-599.
RX   PubMed=11175748; DOI=10.1038/35055065;
RA   Iwawaki T., Hosoda A., Okuda T., Kamigori Y., Nomura-Furuwatari C.,
RA   Kimata Y., Tsuru A., Kohno K.;
RT   "Translational control by the ER transmembrane kinase/ribonuclease IRE1
RT   under ER stress.";
RL   Nat. Cell Biol. 3:158-164(2001).
RN   [10] {ECO:0000305}
RP   FUNCTION, HOMODIMERIZATION, ACTIVITY REGULATION, INTERACTION WITH HSPA5,
RP   AND MUTAGENESIS OF CYS-109; CYS-148 AND CYS-332.
RX   PubMed=12637535; DOI=10.1074/jbc.m300418200;
RA   Liu C.Y., Xu Z., Kaufman R.J.;
RT   "Structure and intermolecular interactions of the luminal dimerization
RT   domain of human IRE1alpha.";
RL   J. Biol. Chem. 278:17680-17687(2003).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-973, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   ADP-RIBOSYLATION BY PARP16.
RX   PubMed=23103912; DOI=10.1038/ncb2593;
RA   Jwa M., Chang P.;
RT   "PARP16 is a tail-anchored endoplasmic reticulum protein required for the
RT   PERK-and IRE1alpha-mediated unfolded protein response.";
RL   Nat. Cell Biol. 14:1223-1230(2012).
RN   [14]
RP   SUBUNIT, AND INTERACTION WITH DNAJB9 AND HSPA5.
RX   PubMed=29198525; DOI=10.1016/j.cell.2017.10.040;
RA   Amin-Wetzel N., Saunders R.A., Kamphuis M.J., Rato C., Preissler S.,
RA   Harding H.P., Ron D.;
RT   "A J-Protein co-chaperone recruits bip to monomerize IRE1 and repress the
RT   unfolded protein response.";
RL   Cell 171:1625-1637(2017).
RN   [15]
RP   INTERACTION WITH RNF13.
RX   PubMed=23378536; DOI=10.1074/jbc.m112.368829;
RA   Arshad M., Ye Z., Gu X., Wong C.K., Liu Y., Li D., Zhou L., Zhang Y.,
RA   Bay W.P., Yu V.C., Li P.;
RT   "RNF13, a RING finger protein, mediates endoplasmic reticulum stress-
RT   induced apoptosis through the inositol-requiring enzyme (IRE1alpha)/c-Jun
RT   NH2-terminal kinase pathway.";
RL   J. Biol. Chem. 288:8726-8736(2013).
RN   [16]
RP   INTERACTION WITH LACC1.
RX   PubMed=31875558; DOI=10.1016/j.celrep.2019.11.105;
RA   Huang C., Hedl M., Ranjan K., Abraham C.;
RT   "LACC1 required for NOD2-induced, ER stress-mediated innate immune outcomes
RT   in human macrophages and LACC1 risk variants modulate these outcomes.";
RL   Cell Rep. 29:4525-4539(2019).
RN   [17] {ECO:0007744|PDB:2HZ6}
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 24-390, SUBUNIT, AND MUTAGENESIS
RP   OF GLN-105; ASP-123 AND TRP-125.
RX   PubMed=16973740; DOI=10.1073/pnas.0606480103;
RA   Zhou J., Liu C.Y., Back S.H., Clark R.L., Peisach D., Xu Z., Kaufman R.J.;
RT   "The crystal structure of human IRE1 luminal domain reveals a conserved
RT   dimerization interface required for activation of the unfolded protein
RT   response.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:14343-14348(2006).
RN   [18] {ECO:0007744|PDB:3P23}
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 547-977 IN COMPLEX WITH ADP,
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AUTOPHOSPHORYLATION, AND
RP   COFACTOR.
RX   PubMed=21317875; DOI=10.1038/emboj.2011.18;
RA   Ali M.M., Bagratuni T., Davenport E.L., Nowak P.R., Silva-Santisteban M.C.,
RA   Hardcastle A., McAndrews C., Rowlands M.G., Morgan G.J., Aherne W.,
RA   Collins I., Davies F.E., Pearl L.H.;
RT   "Structure of the Ire1 autophosphorylation complex and implications for the
RT   unfolded protein response.";
RL   EMBO J. 30:894-905(2011).
RN   [19]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-244; MET-418; ARG-474; TRP-635;
RP   SER-700; PHE-769 AND LEU-830.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [20]
RP   FUNCTION.
RX   PubMed=21884936; DOI=10.1016/j.cell.2011.07.021;
RA   Gee H.Y., Noh S.H., Tang B.L., Kim K.H., Lee M.G.;
RT   "Rescue of DeltaF508-CFTR trafficking via a GRASP-dependent unconventional
RT   secretion pathway.";
RL   Cell 146:746-760(2011).
RN   [21]
RP   FUNCTION, INTERACTION WITH PDIA6, SUBUNIT, AND MUTAGENESIS OF CYS-148.
RX   PubMed=24508390; DOI=10.1016/j.molcel.2014.01.004;
RA   Eletto D., Eletto D., Dersh D., Gidalevitz T., Argon Y.;
RT   "Protein disulfide isomerase A6 controls the decay of IRE1alpha signaling
RT   via disulfide-dependent association.";
RL   Mol. Cell 53:562-576(2014).
RN   [22]
RP   FUNCTION, INTERACTION WITH DDRGK1, AND PHOSPHORYLATION.
RX   PubMed=28128204; DOI=10.1038/ncomms14186;
RA   Liu J., Wang Y., Song L., Zeng L., Yi W., Liu T., Chen H., Wang M., Ju Z.,
RA   Cong Y.S.;
RT   "A critical role of DDRGK1 in endoplasmic reticulum homoeostasis via
RT   regulation of IRE1alpha stability.";
RL   Nat. Commun. 8:14186-14186(2017).
RN   [23]
RP   FUNCTION.
RX   PubMed=28067262; DOI=10.1038/srep39887;
RA   Piao H., Kim J., Noh S.H., Kweon H.S., Kim J.Y., Lee M.G.;
RT   "Sec16A is critical for both conventional and unconventional secretion of
RT   CFTR.";
RL   Sci. Rep. 7:39887-39887(2017).
RN   [24]
RP   INTERACTION WITH P4HB, AND MUTAGENESIS OF CYS-109; CYS-148 AND CYS-332.
RX   PubMed=32149426; DOI=10.15252/embj.2019103841;
RA   Yu J., Li T., Liu Y., Wang X., Zhang J., Wang X., Shi G., Lou J., Wang L.,
RA   Wang C.C., Wang L.;
RT   "Phosphorylation switches protein disulfide isomerase activity to maintain
RT   proteostasis and attenuate ER stress.";
RL   EMBO J. 39:e103841-e103841(2020).
CC   -!- FUNCTION: Serine/threonine-protein kinase and endoribonuclease that
CC       acts as a key sensor for the endoplasmic reticulum unfolded protein
CC       response (UPR) (PubMed:11779464, PubMed:11175748, PubMed:12637535,
CC       PubMed:9637683, PubMed:21317875, PubMed:28128204). In unstressed cells,
CC       the endoplasmic reticulum luminal domain is maintained in its inactive
CC       monomeric state by binding to the endoplasmic reticulum chaperone
CC       HSPA5/BiP (PubMed:21317875). Accumulation of misfolded proteins in the
CC       endoplasmic reticulum causes release of HSPA5/BiP, allowing the luminal
CC       domain to homodimerize, promoting autophosphorylation of the kinase
CC       domain and subsequent activation of the endoribonuclease activity
CC       (PubMed:21317875). The endoribonuclease activity is specific for XBP1
CC       mRNA and excises 26 nucleotides from XBP1 mRNA (PubMed:11779464,
CC       PubMed:24508390, PubMed:21317875). The resulting spliced transcript of
CC       XBP1 encodes a transcriptional activator protein that up-regulates
CC       expression of UPR target genes (PubMed:11779464, PubMed:24508390,
CC       PubMed:21317875). Acts as an upstream signal for ER stress-induced
CC       GORASP2-mediated unconventional (ER/Golgi-independent) trafficking of
CC       CFTR to cell membrane by modulating the expression and localization of
CC       SEC16A (PubMed:21884936, PubMed:28067262).
CC       {ECO:0000269|PubMed:11175748, ECO:0000269|PubMed:11779464,
CC       ECO:0000269|PubMed:12637535, ECO:0000269|PubMed:21317875,
CC       ECO:0000269|PubMed:21884936, ECO:0000269|PubMed:28067262,
CC       ECO:0000269|PubMed:28128204, ECO:0000269|PubMed:9637683,
CC       ECO:0000305|PubMed:24508390}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:9637683};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:21317875,
CC         ECO:0000269|PubMed:9637683};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:9637683};
CC   -!- ACTIVITY REGULATION: The kinase domain is activated by trans-
CC       autophosphorylation following homodimerization (PubMed:12637535,
CC       PubMed:9637683). Kinase activity is required for activation of the
CC       endoribonuclease domain (PubMed:12637535, PubMed:9637683).
CC       Endoribonuclease activity is specifically inhibited by hydroxy-aryl-
CC       aldehydes (HAA) (By similarity). {ECO:0000250|UniProtKB:Q9EQY0,
CC       ECO:0000269|PubMed:12637535, ECO:0000269|PubMed:9637683}.
CC   -!- SUBUNIT: Monomer (PubMed:29198525, PubMed:16973740). Homodimer;
CC       disulfide-linked; homodimerization takes place in response to
CC       endoplasmic reticulum stress and promotes activation of the kinase and
CC       endoribonuclease activities (PubMed:12637535, PubMed:24508390,
CC       PubMed:16973740, PubMed:21317875). Dimer formation is driven by
CC       hydrophobic interactions within the N-terminal luminal domains and
CC       stabilized by disulfide bridges (PubMed:12637535). Interacts (via the
CC       luminal region) with DNAJB9/ERdj4; interaction takes place in
CC       unstressed cells and promotes recruitment of HSPA5/BiP
CC       (PubMed:29198525). Interacts (via the luminal region) with HSPA5/BiP;
CC       HSPA5/BiP is a negative regulator of the unfolded protein response
CC       (UPR) that prevents homodimerization of ERN1/IRE1 and subsequent
CC       activation of the protein (PubMed:12637535, PubMed:29198525). Interacts
CC       with PDIA6, a negative regulator of the UPR; the interaction is direct
CC       and disrupts homodimerization (PubMed:24508390). Interacts with DAB2IP
CC       (via PH domain); the interaction occurs in a endoplasmic reticulum
CC       stress-induced dependent manner and is required for subsequent
CC       recruitment of TRAF2 to ERN1/IRE1 (By similarity). Interacts with TAOK3
CC       and TRAF2 (PubMed:11278723). Interacts with RNF13 (PubMed:23378536).
CC       Interacts with LACC1 (PubMed:31875558). Interacts (when
CC       unphosphorylated) with DDRGK1; interaction is dependent on UFM1 and
CC       takes place in response to endoplasmic reticulum stress, regulating
CC       ERN1/IRE1-alpha stability (PubMed:28128204). Interacts (via N-terminus)
CC       with P4HB/PDIA1; the interaction is enhanced by phosphorylation of P4HB
CC       by FAM20C in response to endoplasmic reticulum stress and results in
CC       attenuation of ERN1 activity (PubMed:32149426).
CC       {ECO:0000250|UniProtKB:Q9EQY0, ECO:0000269|PubMed:11278723,
CC       ECO:0000269|PubMed:12637535, ECO:0000269|PubMed:16973740,
CC       ECO:0000269|PubMed:23378536, ECO:0000269|PubMed:24508390,
CC       ECO:0000269|PubMed:28128204, ECO:0000269|PubMed:29198525,
CC       ECO:0000269|PubMed:31875558, ECO:0000269|PubMed:32149426}.
CC   -!- INTERACTION:
CC       O75460; Q07812: BAX; NbExp=2; IntAct=EBI-371750, EBI-516580;
CC       O75460; O75460: ERN1; NbExp=2; IntAct=EBI-371750, EBI-371750;
CC       O75460; P11021: HSPA5; NbExp=3; IntAct=EBI-371750, EBI-354921;
CC       O75460; Q86TM6: SYVN1; NbExp=2; IntAct=EBI-371750, EBI-947849;
CC       O75460; Q9H2K8: TAOK3; NbExp=3; IntAct=EBI-371750, EBI-1384100;
CC       O75460; Q12933: TRAF2; NbExp=3; IntAct=EBI-371750, EBI-355744;
CC       O75460; Q969M3: YIPF5; NbExp=3; IntAct=EBI-371750, EBI-2124787;
CC       O75460; O08734: Bak1; Xeno; NbExp=2; IntAct=EBI-371750, EBI-822441;
CC       O75460; Q07813: Bax; Xeno; NbExp=2; IntAct=EBI-371750, EBI-700711;
CC       O75460; P20029: Hspa5; Xeno; NbExp=2; IntAct=EBI-371750, EBI-772325;
CC       O75460-1; O75460-1: ERN1; NbExp=5; IntAct=EBI-15600828, EBI-15600828;
CC       O75460-1; P11021: HSPA5; NbExp=4; IntAct=EBI-15600828, EBI-354921;
CC       O75460-1; Q13438: OS9; NbExp=2; IntAct=EBI-15600828, EBI-725454;
CC       O75460-1; Q9UBV2: SEL1L; NbExp=2; IntAct=EBI-15600828, EBI-358766;
CC       O75460-1; Q86TM6: SYVN1; NbExp=3; IntAct=EBI-15600828, EBI-947849;
CC       O75460-2; Q6DHV7-2: ADAL; NbExp=3; IntAct=EBI-25852368, EBI-18899653;
CC       O75460-2; Q96MA6: AK8; NbExp=3; IntAct=EBI-25852368, EBI-8466265;
CC       O75460-2; Q66PJ3-4: ARL6IP4; NbExp=3; IntAct=EBI-25852368, EBI-5280499;
CC       O75460-2; Q9UBL3: ASH2L; NbExp=3; IntAct=EBI-25852368, EBI-540797;
CC       O75460-2; Q96FT7-4: ASIC4; NbExp=3; IntAct=EBI-25852368, EBI-9089489;
CC       O75460-2; Q8TBE0: BAHD1; NbExp=3; IntAct=EBI-25852368, EBI-742750;
CC       O75460-2; Q9BRT8: CBWD1; NbExp=3; IntAct=EBI-25852368, EBI-1054417;
CC       O75460-2; Q9NNX6-10: CD209; NbExp=3; IntAct=EBI-25852368, EBI-12300031;
CC       O75460-2; P38936: CDKN1A; NbExp=3; IntAct=EBI-25852368, EBI-375077;
CC       O75460-2; Q96EY1-3: DNAJA3; NbExp=3; IntAct=EBI-25852368, EBI-11526226;
CC       O75460-2; A0A024RCP2: DOM3Z; NbExp=3; IntAct=EBI-25852368, EBI-25847826;
CC       O75460-2; Q92782-2: DPF1; NbExp=3; IntAct=EBI-25852368, EBI-23669343;
CC       O75460-2; Q06547-2: GABPB1; NbExp=3; IntAct=EBI-25852368, EBI-618189;
CC       O75460-2; Q06547-3: GABPB1; NbExp=3; IntAct=EBI-25852368, EBI-9088619;
CC       O75460-2; P52655: GTF2A1; NbExp=3; IntAct=EBI-25852368, EBI-389518;
CC       O75460-2; Q0VD86: INCA1; NbExp=3; IntAct=EBI-25852368, EBI-6509505;
CC       O75460-2; Q92615: LARP4B; NbExp=3; IntAct=EBI-25852368, EBI-1052558;
CC       O75460-2; Q6PHZ7: NR2C2; NbExp=3; IntAct=EBI-25852368, EBI-2802743;
CC       O75460-2; Q6GQQ9-2: OTUD7B; NbExp=3; IntAct=EBI-25852368, EBI-25830200;
CC       O75460-2; Q8N2H9-4: PELI3; NbExp=3; IntAct=EBI-25852368, EBI-25852006;
CC       O75460-2; O15534: PER1; NbExp=3; IntAct=EBI-25852368, EBI-2557276;
CC       O75460-2; Q58EX7-2: PLEKHG4; NbExp=3; IntAct=EBI-25852368, EBI-21503705;
CC       O75460-2; Q5SXH7-1: PLEKHS1; NbExp=3; IntAct=EBI-25852368, EBI-26412802;
CC       O75460-2; Q14181: POLA2; NbExp=3; IntAct=EBI-25852368, EBI-712752;
CC       O75460-2; Q9UHI5: SLC7A8; NbExp=3; IntAct=EBI-25852368, EBI-13292283;
CC       O75460-2; O14544: SOCS6; NbExp=3; IntAct=EBI-25852368, EBI-3929549;
CC       O75460-2; Q496A3: SPATS1; NbExp=3; IntAct=EBI-25852368, EBI-3923692;
CC       O75460-2; Q8IUR5-4: TMTC1; NbExp=3; IntAct=EBI-25852368, EBI-9089156;
CC       O75460-2; P49459: UBE2A; NbExp=3; IntAct=EBI-25852368, EBI-2339348;
CC       O75460-2; Q9NX94: WBP1L; NbExp=3; IntAct=EBI-25852368, EBI-10316321;
CC       O75460-2; Q9BYN7-2: ZNF341; NbExp=3; IntAct=EBI-25852368, EBI-16435478;
CC       O75460-2; Q3KNS6-3: ZNF829; NbExp=3; IntAct=EBI-25852368, EBI-18036029;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:9637683}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:9637683}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O75460-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O75460-2; Sequence=VSP_034582, VSP_034583;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. High levels observed in
CC       pancreatic tissue. {ECO:0000269|PubMed:9637683}.
CC   -!- PTM: Autophosphorylated following homodimerization. Autophosphorylation
CC       promotes activation of the endoribonuclease domain.
CC       {ECO:0000269|PubMed:12637535, ECO:0000269|PubMed:21317875,
CC       ECO:0000269|PubMed:28128204, ECO:0000269|PubMed:9637683}.
CC   -!- PTM: ADP-ribosylated by PARP16 upon ER stress, which increases both
CC       kinase and endonuclease activities. {ECO:0000269|PubMed:23103912}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein
CC       kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF059198; AAC25991.1; -; mRNA.
DR   EMBL; AK292403; BAF85092.1; -; mRNA.
DR   EMBL; DA254477; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AB209869; BAD93106.1; -; mRNA.
DR   EMBL; AC005803; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC025362; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471109; EAW94214.1; -; Genomic_DNA.
DR   EMBL; BC130405; AAI30406.1; -; mRNA.
DR   EMBL; BC130407; AAI30408.1; -; mRNA.
DR   EMBL; BI912495; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS45762.1; -. [O75460-1]
DR   RefSeq; NP_001424.3; NM_001433.3. [O75460-1]
DR   PDB; 2HZ6; X-ray; 3.10 A; A=24-390.
DR   PDB; 3P23; X-ray; 2.70 A; A/B/C/D=547-977.
DR   PDB; 4U6R; X-ray; 2.50 A; A=547-977.
DR   PDB; 4YZ9; X-ray; 2.46 A; A/B/C=562-966.
DR   PDB; 4YZC; X-ray; 2.49 A; A/B=562-966.
DR   PDB; 4YZD; X-ray; 3.10 A; A/B/C=562-966.
DR   PDB; 4Z7G; X-ray; 2.60 A; A/B=562-977.
DR   PDB; 4Z7H; X-ray; 2.90 A; A/B=562-977.
DR   PDB; 5HGI; X-ray; 2.58 A; A=547-977.
DR   PDB; 6HV0; X-ray; 2.73 A; A=562-977.
DR   PDB; 6HX1; X-ray; 2.14 A; A=562-964.
DR   PDB; 6SHC; X-ray; 3.55 A; A=24-390.
DR   PDB; 6URC; X-ray; 2.20 A; A/B=547-977.
DR   PDB; 6W39; X-ray; 1.74 A; A/B=547-977.
DR   PDB; 6W3A; X-ray; 2.61 A; A/B=547-977.
DR   PDB; 6W3B; X-ray; 2.57 A; A=547-977.
DR   PDB; 6W3C; X-ray; 2.30 A; A/B/C/D=547-977.
DR   PDB; 6W3E; X-ray; 2.74 A; A/B=547-977.
DR   PDB; 6W3K; X-ray; 2.08 A; A=547-977.
DR   PDB; 6XDB; X-ray; 2.45 A; A=547-977.
DR   PDB; 6XDD; X-ray; 2.40 A; A/B=547-977.
DR   PDB; 6XDF; X-ray; 2.54 A; A/B=547-977.
DR   PDB; 7BMK; X-ray; 1.85 A; A/B=547-977.
DR   PDBsum; 2HZ6; -.
DR   PDBsum; 3P23; -.
DR   PDBsum; 4U6R; -.
DR   PDBsum; 4YZ9; -.
DR   PDBsum; 4YZC; -.
DR   PDBsum; 4YZD; -.
DR   PDBsum; 4Z7G; -.
DR   PDBsum; 4Z7H; -.
DR   PDBsum; 5HGI; -.
DR   PDBsum; 6HV0; -.
DR   PDBsum; 6HX1; -.
DR   PDBsum; 6SHC; -.
DR   PDBsum; 6URC; -.
DR   PDBsum; 6W39; -.
DR   PDBsum; 6W3A; -.
DR   PDBsum; 6W3B; -.
DR   PDBsum; 6W3C; -.
DR   PDBsum; 6W3E; -.
DR   PDBsum; 6W3K; -.
DR   PDBsum; 6XDB; -.
DR   PDBsum; 6XDD; -.
DR   PDBsum; 6XDF; -.
DR   PDBsum; 7BMK; -.
DR   AlphaFoldDB; O75460; -.
DR   SMR; O75460; -.
DR   BioGRID; 108391; 61.
DR   DIP; DIP-31711N; -.
DR   IntAct; O75460; 56.
DR   MINT; O75460; -.
DR   STRING; 9606.ENSP00000401445; -.
DR   BindingDB; O75460; -.
DR   ChEMBL; CHEMBL1163101; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB07382; N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine.
DR   DrugCentral; O75460; -.
DR   GuidetoPHARMACOLOGY; 2020; -.
DR   TCDB; 8.A.104.1.9; the 5'-amp-activated protein kinase (ampk) family.
DR   GlyGen; O75460; 1 site.
DR   iPTMnet; O75460; -.
DR   PhosphoSitePlus; O75460; -.
DR   BioMuta; ERN1; -.
DR   EPD; O75460; -.
DR   jPOST; O75460; -.
DR   MassIVE; O75460; -.
DR   MaxQB; O75460; -.
DR   PaxDb; O75460; -.
DR   PeptideAtlas; O75460; -.
DR   PRIDE; O75460; -.
DR   ProteomicsDB; 50021; -. [O75460-1]
DR   Antibodypedia; 4011; 719 antibodies from 43 providers.
DR   DNASU; 2081; -.
DR   Ensembl; ENST00000433197.4; ENSP00000401445.2; ENSG00000178607.17. [O75460-1]
DR   Ensembl; ENST00000606895.2; ENSP00000475519.1; ENSG00000178607.17. [O75460-2]
DR   GeneID; 2081; -.
DR   KEGG; hsa:2081; -.
DR   MANE-Select; ENST00000433197.4; ENSP00000401445.2; NM_001433.5; NP_001424.3.
DR   UCSC; uc002jdz.3; human. [O75460-1]
DR   CTD; 2081; -.
DR   DisGeNET; 2081; -.
DR   GeneCards; ERN1; -.
DR   HGNC; HGNC:3449; ERN1.
DR   HPA; ENSG00000178607; Tissue enhanced (adrenal gland, pancreas).
DR   MIM; 604033; gene.
DR   neXtProt; NX_O75460; -.
DR   OpenTargets; ENSG00000178607; -.
DR   PharmGKB; PA27861; -.
DR   VEuPathDB; HostDB:ENSG00000178607; -.
DR   eggNOG; KOG1027; Eukaryota.
DR   GeneTree; ENSGT00940000159761; -.
DR   HOGENOM; CLU_004875_1_1_1; -.
DR   InParanoid; O75460; -.
DR   OMA; HYLPDPR; -.
DR   OrthoDB; 1019877at2759; -.
DR   PhylomeDB; O75460; -.
DR   TreeFam; TF313986; -.
DR   PathwayCommons; O75460; -.
DR   Reactome; R-HSA-381070; IRE1alpha activates chaperones.
DR   SignaLink; O75460; -.
DR   SIGNOR; O75460; -.
DR   BioGRID-ORCS; 2081; 13 hits in 1109 CRISPR screens.
DR   ChiTaRS; ERN1; human.
DR   EvolutionaryTrace; O75460; -.
DR   GeneWiki; ERN1; -.
DR   GenomeRNAi; 2081; -.
DR   Pharos; O75460; Tchem.
DR   PRO; PR:O75460; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; O75460; protein.
DR   Bgee; ENSG00000178607; Expressed in parotid gland and 157 other tissues.
DR   Genevisible; O75460; HS.
DR   GO; GO:1990597; C:AIP1-IRE1 complex; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0030176; C:integral component of endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:1990332; C:Ire1 complex; NAS:ParkinsonsUK-UCL.
DR   GO; GO:1990630; C:IRE1-RACK1-PP2A complex; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1990604; C:IRE1-TRAF2-ASK1 complex; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0005637; C:nuclear inner membrane; IEA:Ensembl.
DR   GO; GO:0043531; F:ADP binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0004521; F:endoribonuclease activity; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0030544; F:Hsp70 protein binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0051879; F:Hsp90 protein binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0005161; F:platelet-derived growth factor receptor binding; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0051082; F:unfolded protein binding; IBA:GO_Central.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0034620; P:cellular response to unfolded protein; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0001935; P:endothelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:1901142; P:insulin metabolic process; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; ISS:UniProtKB.
DR   GO; GO:0036498; P:IRE1-mediated unfolded protein response; IDA:UniProtKB.
DR   GO; GO:0006402; P:mRNA catabolic process; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0006379; P:mRNA cleavage; ISS:UniProtKB.
DR   GO; GO:0098787; P:mRNA cleavage involved in mRNA processing; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0070054; P:mRNA splicing, via endonucleolytic cleavage and ligation; IDA:UniProtKB.
DR   GO; GO:0036289; P:peptidyl-serine autophosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1990579; P:peptidyl-serine trans-autophosphorylation; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1900103; P:positive regulation of endoplasmic reticulum unfolded protein response; IMP:UniProtKB.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0033120; P:positive regulation of RNA splicing; IDA:UniProtKB.
DR   GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0016241; P:regulation of macroautophagy; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; IDA:ParkinsonsUK-UCL.
DR   Gene3D; 1.20.1440.180; -; 1.
DR   Gene3D; 2.130.10.10; -; 1.
DR   InterPro; IPR045133; IRE1/2-like.
DR   InterPro; IPR010513; KEN_dom.
DR   InterPro; IPR038357; KEN_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR018391; PQQ_beta_propeller_repeat.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR011047; Quinoprotein_ADH-like_supfam.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf.
DR   PANTHER; PTHR13954; PTHR13954; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF06479; Ribonuc_2-5A; 1.
DR   SMART; SM00564; PQQ; 5.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF50998; SSF50998; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51392; KEN; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Alternative splicing; Apoptosis;
KW   ATP-binding; Disulfide bond; Endoplasmic reticulum; Glycoprotein;
KW   Hydrolase; Kinase; Magnesium; Membrane; Metal-binding;
KW   Multifunctional enzyme; Nucleotide-binding; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase; Signal; Transcription;
KW   Transcription regulation; Transferase; Transmembrane; Transmembrane helix;
KW   Unfolded protein response.
FT   SIGNAL          1..18
FT                   /evidence="ECO:0000255"
FT   CHAIN           19..977
FT                   /note="Serine/threonine-protein kinase/endoribonuclease
FT                   IRE1"
FT                   /id="PRO_0000024327"
FT   TOPO_DOM        19..443
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        444..464
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        465..977
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          571..832
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          835..963
FT                   /note="KEN"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00725"
FT   REGION          410..434
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          491..559
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          906..907
FT                   /note="Interacts with hydroxy-aryl-aldehyde inhibitors"
FT                   /evidence="ECO:0000250|UniProtKB:Q9EQY0"
FT   COMPBIAS        511..551
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        688
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250|UniProtKB:P32361,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE-
FT                   ProRule:PRU10027"
FT   BINDING         577..585
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P32361,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         599
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:9637683,
FT                   ECO:0007744|PDB:3P23"
FT   BINDING         643..645
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:21317875,
FT                   ECO:0007744|PDB:3P23"
FT   BINDING         690..693
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:21317875,
FT                   ECO:0007744|PDB:3P23"
FT   BINDING         711
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:21317875,
FT                   ECO:0007744|PDB:3P23"
FT   SITE            892
FT                   /note="Interacts with hydroxy-aryl-aldehyde inhibitors"
FT                   /evidence="ECO:0000250|UniProtKB:Q9EQY0"
FT   MOD_RES         973
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   CARBOHYD        176
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         19..70
FT                   /note="IFGSTSTVTLPETLLFVSTLDGSLHAVSKRTGSIKWTLKEDPVLQVPTHVEE
FT                   -> VSDRGAWGGGQLATAGSGPGQRRGAGAGVRAGSATAAARCPVSPAVGGSGRA (in
FT                   isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_034582"
FT   VAR_SEQ         71..977
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_034583"
FT   VARIANT         244
FT                   /note="N -> S (in a renal clear cell carcinoma sample;
FT                   somatic mutation; dbSNP:rs1397145500)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040488"
FT   VARIANT         418
FT                   /note="V -> M (in dbSNP:rs55869215)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040489"
FT   VARIANT         474
FT                   /note="L -> R (in a lung adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs186305118)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040490"
FT   VARIANT         635
FT                   /note="R -> W (in a gastric adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs146710304)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040491"
FT   VARIANT         700
FT                   /note="N -> S (in dbSNP:rs918253870)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040492"
FT   VARIANT         769
FT                   /note="S -> F (in a glioblastoma multiforme sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040493"
FT   VARIANT         830
FT                   /note="P -> L (in an ovarian serous carcinoma sample;
FT                   somatic mutation; dbSNP:rs1279653488)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040494"
FT   MUTAGEN         105
FT                   /note="Q->E: Impaired ability to homodimerize."
FT                   /evidence="ECO:0000269|PubMed:16973740"
FT   MUTAGEN         109
FT                   /note="C->S: No effect on dimerization. No effect on
FT                   interaction with P4HB; when associated with S-148 and
FT                   S-332."
FT                   /evidence="ECO:0000269|PubMed:12637535,
FT                   ECO:0000269|PubMed:32149426"
FT   MUTAGEN         123
FT                   /note="D->P: Abolishes ability to homodimerize."
FT                   /evidence="ECO:0000269|PubMed:16973740"
FT   MUTAGEN         125
FT                   /note="W->A: Abolishes ability to homodimerize."
FT                   /evidence="ECO:0000269|PubMed:16973740"
FT   MUTAGEN         148
FT                   /note="C->S: No effect on dimerization. Weakens dimer; when
FT                   associated with S-332. Abolishes interaction with PDIA6.
FT                   Prolonged splicing of XBP1, probably due to prolonged
FT                   activation of PDIA6. Inhibits formation of oxidized
FT                   multimeric forms of ERN1 in response to ER stress. No
FT                   effect on interaction with P4HB; when associated with S-109
FT                   and S-332."
FT                   /evidence="ECO:0000269|PubMed:12637535,
FT                   ECO:0000269|PubMed:24508390, ECO:0000269|PubMed:32149426"
FT   MUTAGEN         332
FT                   /note="C->S: No effect on dimerization. Weakens dimer; when
FT                   associated with S-148. No effect on interaction with P4HB;
FT                   when associated with S-109 and S-148."
FT                   /evidence="ECO:0000269|PubMed:12637535,
FT                   ECO:0000269|PubMed:32149426"
FT   MUTAGEN         599
FT                   /note="K->A: Loss of autophosphorylation and of
FT                   endoribonuclease activity. Inhibition of growth arrest."
FT                   /evidence="ECO:0000269|PubMed:11175748,
FT                   ECO:0000269|PubMed:9637683"
FT   CONFLICT        190..191
FT                   /note="DV -> EG (in Ref. 1; AAC25991)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        768
FT                   /note="I -> V (in Ref. 1; AAC25991)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        816
FT                   /note="D -> G (in Ref. 2; BAF85092)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        824..825
FT                   /note="KH -> ND (in Ref. 1; AAC25991)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        880
FT                   /note="V -> D (in Ref. 1; AAC25991)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        904
FT                   /note="M -> T (in Ref. 2; BAF85092)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        924
FT                   /note="S -> T (in Ref. 1; AAC25991)"
FT                   /evidence="ECO:0000305"
FT   STRAND          32..37
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   STRAND          40..46
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   TURN            47..49
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   STRAND          52..57
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   STRAND          73..75
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   TURN            77..79
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   STRAND          82..84
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   STRAND          93..95
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   HELIX           100..104
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   STRAND          120..128
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   STRAND          154..164
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   STRAND          168..172
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   STRAND          176..182
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   STRAND          197..201
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   STRAND          205..209
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   TURN            211..213
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   STRAND          216..221
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   STRAND          226..231
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   STRAND          238..240
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   STRAND          243..246
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   HELIX           247..264
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   HELIX           273..279
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   STRAND          280..284
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   STRAND          286..288
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   STRAND          297..300
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   TURN            359..361
FT                   /evidence="ECO:0007829|PDB:2HZ6"
FT   STRAND          564..566
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   STRAND          569..578
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   HELIX           581..583
FT                   /evidence="ECO:0007829|PDB:6HX1"
FT   STRAND          585..591
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   STRAND          594..601
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   HELIX           603..605
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   HELIX           606..619
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   STRAND          628..633
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   STRAND          638..643
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   STRAND          645..648
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   HELIX           649..654
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   STRAND          655..657
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   HELIX           658..661
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   HELIX           665..681
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   HELIX           691..693
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   STRAND          694..697
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   STRAND          701..703
FT                   /evidence="ECO:0007829|PDB:6W3E"
FT   STRAND          707..709
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   STRAND          711..716
FT                   /evidence="ECO:0007829|PDB:6HX1"
FT   STRAND          718..721
FT                   /evidence="ECO:0007829|PDB:6HV0"
FT   STRAND          723..727
FT                   /evidence="ECO:0007829|PDB:6HX1"
FT   STRAND          729..731
FT                   /evidence="ECO:0007829|PDB:6HV0"
FT   TURN            732..736
FT                   /evidence="ECO:0007829|PDB:6HV0"
FT   HELIX           740..743
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   STRAND          744..746
FT                   /evidence="ECO:0007829|PDB:6XDF"
FT   HELIX           754..768
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   TURN            778..780
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   HELIX           781..787
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   STRAND          793..795
FT                   /evidence="ECO:0007829|PDB:4YZC"
FT   HELIX           800..812
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   HELIX           817..819
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   HELIX           823..827
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   HELIX           830..832
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   HELIX           835..848
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   TURN            849..851
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   STRAND          854..856
FT                   /evidence="ECO:0007829|PDB:4YZ9"
FT   HELIX           857..863
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   HELIX           866..869
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   HELIX           874..876
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   HELIX           880..884
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   TURN            887..890
FT                   /evidence="ECO:0007829|PDB:6W3K"
FT   HELIX           897..909
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   HELIX           911..913
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   HELIX           916..922
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   HELIX           927..936
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   HELIX           940..947
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   HELIX           948..951
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   STRAND          952..954
FT                   /evidence="ECO:0007829|PDB:3P23"
FT   HELIX           955..957
FT                   /evidence="ECO:0007829|PDB:6W39"
FT   TURN            958..960
FT                   /evidence="ECO:0007829|PDB:6W39"
SQ   SEQUENCE   977 AA;  109735 MW;  A2DF808CCE015536 CRC64;
     MPARRLLLLL TLLLPGLGIF GSTSTVTLPE TLLFVSTLDG SLHAVSKRTG SIKWTLKEDP
     VLQVPTHVEE PAFLPDPNDG SLYTLGSKNN EGLTKLPFTI PELVQASPCR SSDGILYMGK
     KQDIWYVIDL LTGEKQQTLS SAFADSLCPS TSLLYLGRTE YTITMYDTKT RELRWNATYF
     DYAASLPEDD VDYKMSHFVS NGDGLVVTVD SESGDVLWIQ NYASPVVAFY VWQREGLRKV
     MHINVAVETL RYLTFMSGEV GRITKWKYPF PKETEAKSKL TPTLYVGKYS TSLYASPSMV
     HEGVAVVPRG STLPLLEGPQ TDGVTIGDKG ECVITPSTDV KFDPGLKSKN KLNYLRNYWL
     LIGHHETPLS ASTKMLERFP NNLPKHRENV IPADSEKKSF EEVINLVDQT SENAPTTVSR
     DVEEKPAHAP ARPEAPVDSM LKDMATIILS TFLLIGWVAF IITYPLSMHQ QQQLQHQQFQ
     KELEKIQLLQ QQQQQLPFHP PGDTAQDGEL LDTSGPYSES SGTSSPSTSP RASNHSLCSG
     SSASKAGSSP SLEQDDGDEE TSVVIVGKIS FCPKDVLGHG AEGTIVYRGM FDNRDVAVKR
     ILPECFSFAD REVQLLRESD EHPNVIRYFC TEKDRQFQYI AIELCAATLQ EYVEQKDFAH
     LGLEPITLLQ QTTSGLAHLH SLNIVHRDLK PHNILISMPN AHGKIKAMIS DFGLCKKLAV
     GRHSFSRRSG VPGTEGWIAP EMLSEDCKEN PTYTVDIFSA GCVFYYVISE GSHPFGKSLQ
     RQANILLGAC SLDCLHPEKH EDVIARELIE KMIAMDPQKR PSAKHVLKHP FFWSLEKQLQ
     FFQDVSDRIE KESLDGPIVK QLERGGRAVV KMDWRENITV PLQTDLRKFR TYKGGSVRDL
     LRAMRNKKHH YRELPAEVRE TLGSLPDDFV CYFTSRFPHL LAHTYRAMEL CSHERLFQPY
     YFHEPPEPQP PVTPDAL
//
